In non-small cell lung cancer, a novel 4′-brominated derivative of fisetin inhibits the EGFR/ERK1/2/STAT3 pathways and causes cell cycle arrest and apoptosis without having any negative effects on mice. Here, STAT3 is linked to non-small cell lung carcinoma.